Published in Pharmacoeconomics on January 01, 2005
Health care charges for youth with newly diagnosed epilepsy. Neurology (2015) 1.49
Determining surgical candidacy in temporal lobe epilepsy. Epilepsy Res Treat (2012) 0.80
The economic impact of epilepsy: a systematic review. BMC Neurol (2015) 0.76
Quality of Life Changes and Health Care Charges Among Youth With Epilepsy. J Pediatr Psychol (2015) 0.75
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst (2007) 2.01
Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy (2006) 1.87
Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med (2011) 1.72
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer (2010) 1.50
Primary prevention of epilepsy in patients with different epileptogenic conditions. Expert Rev Neurother (2004) 1.41
The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics (2012) 1.18
Pharmaceutical policy in Italy: towards a structural change? Health Policy (2005) 1.15
Headache, anxiety and depressive disorders: the HADAS study. J Headache Pain (2010) 1.07
Comment on: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers". Appl Health Econ Health Policy (2014) 1.06
Chemotherapy-induced neuropathy. Curr Treat Options Neurol (2011) 0.99
Learning disorders in epilepsy. Epilepsia (2006) 0.99
Aggression in psychiatry wards: a systematic review. Psychiatry Res (2011) 0.98
Should we really worry about "launch delays" of new drugs in OECD countries? Eur J Health Econ (2007) 0.96
Continuing Medical Education in six European countries: a comparative analysis. Health Policy (2009) 0.93
Correlation between cognition and behavior in epilepsy. Epilepsia (2006) 0.93
A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy (2014) 0.92
Health status, resource consumption, and costs of dysthymia. A multi-center two-year longitudinal study. J Affect Disord (2005) 0.90
Pain in primary care: an Italian survey. Eur J Public Health (2005) 0.89
Economic evaluations in Italy: a review of the literature. Int J Technol Assess Health Care (2003) 0.87
Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ (2015) 0.86
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst (2008) 0.86
Drug sales in four European countries still differ. BMJ (2003) 0.85
Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics (2014) 0.84
Biosimilar versus generic drugs: same but different? Appl Health Econ Health Policy (2015) 0.83
The Bayesian model on human papillomavirus vaccination in Italy lacks transparency. Med Care (2013) 0.83
Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia (2004) 0.82
Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ (2011) 0.82
Economic analysis of newer antiepileptic drugs. CNS Drugs (2008) 0.81
Epilepsy and family expressed emotion: results of a prospective study. Seizure (2007) 0.81
Health technology assessment: for whom the bell tolls? Eur J Health Econ (2008) 0.81
Accidents at work among people with epilepsy. Results of a European prospective cohort study. Seizure (2006) 0.80
TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci (2014) 0.80
HPV vaccination for boys? Talking economic sense. J Sex Med (2012) 0.80
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst (2014) 0.79
Catatonic psychosis related to forced normalization in a girl with Dravet's syndrome. Epileptic Disord (2008) 0.79
Healthcare costs of COPD in Italian referral centres: a prospective study. Respir Med (2007) 0.79
Could co-payments on drugs help to make EU health care systems less open to political influence? Eur J Health Econ (2013) 0.77
Conversation analysis in the differential diagnosis of Italian patients with epileptic or psychogenic non-epileptic seizures: a blind prospective study. Epilepsy Behav (2012) 0.77
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. J Peripher Nerv Syst (2014) 0.77
Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. J Med Econ (2008) 0.76
Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue. Drugs Aging (2009) 0.76
Re: The health technology assessment of bivalent HPV vaccine Cervarix® in Italy. Vaccine (2011) 0.75
HPV vaccine prices in Italy. BMJ (2011) 0.75
Utilities and QALYs in health economic evaluations: glossary and introduction. Intern Emerg Med (2010) 0.75
Health status, resource consumption, and costs of dysthymic patients in Italian primary care. Epidemiol Psichiatr Soc (2004) 0.75
Direct medical costs of monitoring and treating patients with Takayasu arteritis in Italy. Eur J Health Econ (2004) 0.75
The stoma appliances market in five European countries: a comparative analysis. Appl Health Econ Health Policy (2002) 0.75
Psychiatric events in epilepsy. Seizure (2007) 0.75
Optional copayments on anti-cancer drugs. BMJ (2013) 0.75
Direct medical costs of mycosis fungoides in specialized Italian hospital departments. Haematologica (2005) 0.75
A critical review of the full economic evaluations of pharmacological treatments for glaucoma. J Med Econ (2008) 0.75
Mood disorder with psychotic symptoms and overlooked skin lesions: the strange case of Mrs. O. Riv Psichiatr (2012) 0.75
Partial seizures with affective semiology versus pavor nocturnus. Epileptic Disord (2010) 0.75
The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications? Expert Rev Neurother (2011) 0.75
[Pharmacoeconomic evaluations on antipsychotics in schizophrenia: a review of the Italian studies]. Epidemiol Psichiatr Soc (2006) 0.75
Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study. Ophthalmologica (2007) 0.75
Vaccination planning and vaccine prices in a decentralizing country - Italy. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
Pharmaceutical policy in Italy: Theory, politics and practice. Eur J Health Econ (2006) 0.75
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. Neurology (2017) 0.75
[Residential facilities and day centres in mental health. Is there any difference?]. Epidemiol Psichiatr Soc (2008) 0.75
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue. Pain Manag (2013) 0.75
To model or not to model: lessons from two vaccinations. Eur J Health Econ (2011) 0.75